Transmedics Group, Inc. revenue
Transmedics Group, Inc.'s revenue was $605m in fiscal 2025, up 37.1% on the year before. Since fiscal 2018 ($13.0m) it has grown at a compound 73.1% a year. Over the last twelve months it was $668m.
Revenue history
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 24 | 26 | 30 | 93 | 242 | 442 | 605 | 668 |
| Growth on the year before | — | +81.3% | +8.6% | +18.0% | +208.8% | +158.5% | +82.7% | +37.1% | — |
| Gross profit | 6 | 14 | 17 | 21 | 65 | 154 | 262 | 363 | 392 |
| Gross margin | 44.1% | 58.7% | 64.9% | 69.9% | 69.8% | 63.8% | 59.4% | 59.9% | 58.7% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $372M | 61.1% | ▲ 36.0% |
| Services | $233M | 38.2% | ▲ 39.0% |
| Service Unrelated To OCS Transplant | $4.1M | 0.7% | ▼ 6.8% |
From Transmedics Group, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Transmedics Group, Inc. | $668m | 25.8% | 64.2% |
| Glaukos Corp | $690m | 46.9% | 31.5% |
| Novocure Ltd | $725m | 12.9% | 12.9% |
| Bioventus Inc. | $586m | 3.9% | 5.2% |
| Atricure, Inc. | $570m | 13.9% | 15.9% |
| Myriad Genetics Inc | $807m | -3.2% | 4.9% |
Compare with peers
- Glaukos Corp revenue
- Novocure Ltd revenue
- Bioventus Inc. revenue
- Atricure, Inc. revenue
- Myriad Genetics Inc revenue
Head to head: GKOS vs TMDXNVCR vs TMDXBVS vs TMDXATRC vs TMDX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies